I briefly discuss three components of the media that play a role in the commercialization of medicine: advertising, television dramas, and journalism.
As background, we have to acknowledge the deference paid to consumer choice in our free-market society. Stroll through any shopping mall, supermarket, or car lot and observe the enormous energy devoted to luring the customer to choose one item among a fabulous array of competing items. As Joseph Fins has pointed out, this shopping mall approach was employed in the doomed effort by the Clinton administration to achieve a socially conscious system of universal health insurance. Politicians, healthcare entrepreneurs, and economists argued that the provision and rationing of healthcare should be determined the American way—by “managed competition,” namely, having purveyors of health plans compete for customers by offering them services and premiums determined by what they are willing to pay for. Should doctors accept this role and do whatever they are paid to do? Answering this question affirmatively inevitably validates demands for futile treatment and insurance coverage of unproven treatments, for it logically follows that, if the patient (or someone) is willing to pay for something—anything, why not do it?
While considering this question, we also should note that society has increasingly “medicalized” life. According to the social critic Ivan Illich, people who are preoccupied with the ordinary fatigues and aches and pains of living rarely want to acknowledge that they are unhappy with their jobs or their relationships, or despondent because they are trapped in stressful, unfulfilling life pursuits, or experiencing existential despair. Rather, they want to hear that they are medically ill for which medicine must assume responsibility. “Diagnosed ill-health,” says Illich, “is infinitely preferable to any other form of negative label or to no label at all” (pp. 123–124).1
Illich I. Medical Nemesis: The Expropriation of Health. New York: Pantheon Books; 1976.
Advertising
A recent development reveals how the above two forces—consumer choice and the medicalization of life—have converged: direct medical advertising to the public with a very appealing message: People now can choose from a vast array of drugs for whatever they themselves decide are intolerable medical problems. Needless to say, drug companies are more than willing to go along with the notion that life is full of illness—not “stressful unfulfilling life pursuits” or “existential despair,” but Gastro-Esophageal Reflux Disorder, Chronic Fatigue Syndrome, and exercise-induced Polymyalgia—for which their drugs are the cure. Between 1996 and 2000, drug companies tripled overall advertising spending directed at the general public to nearly $2.5 billion a year. Celebrities, sports stars, movie stars, and other beautiful people dispense enthusiastic medical advice while doing cartwheels, slamming tennis balls, and lounging in hot tubs.
Drug companies have discovered that direct-to-consumer advertising does indeed lead patients to pressure their doctors to prescribe certain drugs.2
Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 2005;352(4):325–8.
Mello MM, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements with industry. New England Journal of Medicine 2005;352;2202–10; Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry—Self-regulation in the shadow of federal prosecution. New England Journal of Medicine 2004;351:1891–900.
Manning S, Schneiderman LJ. Miracles or limits: What message from the medical marketplace? HEC Forum 1996;8(1):103–8.
Yet, vulnerable as they may be, patients are not the primary target of the drug industry. In fact, the industry directs only 16% of the estimated total $13–15 billion spent on drug promotion at the public.5
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. New England Journal of Medicine 2002;346:498–505.
Blumenthal D. Doctors and drug companies. New England Journal of Medicine 2004;351:1885–90.
The resulting conflict of interest has become so pervasive, spreading to industry-sponsored researchers, members of guideline panels and review boards, contract research organizations, the Physicians' Desk Reference, and even to the leading scientists at the National Institutes of Health, that articles have appeared in two major medical journals with the titles, “Just How Tainted Has Medicine Become?”7
Editorial. Just how tainted has medicine become? The Lancet 2002;359:1167.
Kassirer JP. Financial indigestion. JAMA 2000;284:2156–7.
And although drug companies trumpet their dedication to medical research, they spend about twice their revenue on marketing (about 35%) than on research. What can they count on? The advertising pitch for prescribing anti-inflammatory drugs, such as Vioxx and Celebrex, which cost 15 to 18 times as much as over-the-counter painkillers such as ibuprofen and aspirin, is that they are safer for patients at increased risk for adverse gastrointestinal complications. But, in a clear example of “therapeutic creep,”9
“Therapeutic creep” is a play on the military term “mission creep,” in which armed forces find themselves stretched beyond the original planned target, often with unwelcome consequences. In the case of the anti-inflammatory drugs Vioxx and Celebrex, the unwelcome consequence is the soaring costs they imposed on healthcare. Their original indication was limited to patients with increased risk of gastrointestinal bleeding. But with forceful promotion these drugs became the first choice for all patients, even those with no risk of needing such expensive drugs.
Dai C, Stafford RS, Alexander GC. National trends in Cyclooxygenase-2 inhibitor use since market release. Archives of Internal Medicine 2005;165:171–7.
Television Dramas
Another way the public is misled by the media is through the very popular and profitable medical dramas on commercial television. Despite numerous studies published in medical journals that have pointed out the dismally low rate of success (less than 10%) for attempted cardio-pulmonary resuscitation (CPR) in hospitalized patients, there is one exception: CPR performed in television hospitals, where the success rate is sensationally better. After watching all the episodes of ER and Chicago Hope during the 1994–1995 viewing season and 50 consecutive episodes of Rescue 911 during 1995, researchers counted 60 occurrences of CPR. These predominantly involved children and young adults—a very unrepresentative sample. The success rate was 75% with 67% apparently surviving to hospital discharge. The authors concluded that these results “may lead the viewing public to have an unrealistic impression of CPR and its chances for success” (p. 1578).11
Diem SJ, Lantos JD, Tulsky JA. Cardiopulmonary resuscitation on television: Miracles and misinformation. New England Journal of Medicine 1996;334:1578–82.
Murphy DJ, Burrows D, Santilli S, Kemp AW, Tenner S, Kreling B, Teno J. The influence of the probability of survival on patients' preferences regarding cardiopulmonary resuscitation. New England Journal of Medicine 1994;330:545–9.
Journalism
Although I am not sure how true it is, people today are said to be conditioned to the excesses and distortions of advertising and drama and prepared to discount them. But what about journalism? For our free-market society to work fairly and efficiently, journalism has to provide accurate information, the necessary grounding for authentic consumer choice. It is the medium that indeed mediates between the seller and the buyer, the policymaker and the voter, the event and those who did not witness the event.
Unfortunately, most journalists apparently cannot understand much less present medical information accurately. They contribute more to hyperbole than to accuracy. Complain to them and they will protest it not always their fault. They will tell you, as they have told me, that the first priority of owners, editors, and publishers is not so much to inform as to entertain, to sell their product, whether it is a newspaper or a television station. Stories have to be “punched up.” Details are boring and therefore dispensable. Experts cooperate by providing catchy opinions without revealing their conflict of interest. What is lost in this submersion in commercialism is a truly informed public (and, I might add, electorate).
It is a shame that, in the media frenzy over the Vioxx and Celebrex controversies, journalism failed to provide clear information and analysis that would have permitted authentic consumer choice. The drug maker Merck admitted that serious thrombotic events (including heart attack and stroke) were associated with Vioxx, prompting shrill headlines. The relative risks certainly were scary (more than twice the risk!), but the much smaller absolute risk, that is, the actual increase in the number of patients affected (less than 1%) was not presented for public consideration.
Merck executives did not try to explain this important distinction between relative risk and absolute risk to the public. Rather they sent nervous documents back and forth as they debated for years what to do about the unsettling data. When the press got hold of these documents, a scandal erupted, the media leaped to compete for the public's attention, and the drug was pulled.
Imagine a different approach. Rather than huddling over the data behind closed doors, Merck executives call a press conference to open to the public the issues they faced. These drugs—like all drugs—had both risks (in this case, heart attack and stroke) and possible benefits (reducing the risk of bowel cancer). Would the press have been willing to join them in this more difficult and less sensational enterprise? Would journalists have been capable of explaining the data and elucidating the issue of how to weigh risk versus benefit? Would Merck have trusted them to do so? Would this have changed this state of affairs and enhanced true consumer choice?
In a nice irony, it may well turn out in the end that the journalistic media, which I have just taken to task, may be the agent that shames the medical profession into behaving ethically. Recently, the New York Times has started attaching an informative qualifier of conflict of interest when a scientist or physician is quoted in a medical story. For example, in a report on the value of CRP as a predictor of heart disease, the by-lined reporter Gina Kolata has these inserts within parentheses: “(Dr. Rader [who wasn't so impressed with CRP as a predictor compared to cholesterol] consults for and receives honorariums from the drug companies that make statins, drugs sold to lower cholesterol levels.)” “(Dr. Ridker [who is impressed with the CRP data] is an inventor of a test of CRP and profits from its use.)” “(Dr. Jialal [who holds to the inflammatory theory of CRP] is on the advisory boards for Merck, which made Vioxx, and Pfizer, which makes Celebrex.).” Only one cited authority, “(Dr. James Cleeman [who is skeptical about the studies so far] … does not receive support or honorariums from any drug companies.).”13
Kolata G. A study's implications: Drugs that reduce one danger have been shown to create another. New York Times 2005 Jan 7:A17.
It will be interesting to see whether this form of outing becomes a journalistic standard, the media's repentance—and revenge.
